Today on India Upfront, we will talk about the efficacy and safety of covaxin. In view of the accelerated approval, the lack of clarification on Covaxin has been compounded by numerous statements from the authorities. The approval for Covaxin was justified by ICMR chief Balaram Bhargava, citing immunogenicity and safety evidence from phase 2 clinical trials as surrogates for eventual efficacy.
Manufacturer Bharat Biotech dispatched the first batch of Covaxin vaccine against Covid-19 from Hyderabad on Wednesday to 11 cities across the country. Covaxin will be part of the government's mass vaccination program against Covid-19 beginning on Friday, along with the Serum Institute of India's Covishield, which was shipped out on Tuesday.